Scroll

cannabidiol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5288	13956-29-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cannabidiol GWP42003-P epidiolex	The precise mechanisms by which cannabidiol exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors. Molecular weight: 314.47 Formula: C21H30O2 CLOGP: LIPINSKI: None HAC: 2 HDO: 2 TPSA: 40.46 ALOGS: ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cannabidiol
GWP42003-P
epidiolex

The precise mechanisms by which cannabidiol exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.

Molecular weight: 314.47
Formula: C21H30O2
CLOGP:
LIPINSKI: None
HAC: 2
HDO: 2
TPSA: 40.46
ALOGS:
ROTB: 6

Drug dosage:

Dose	Unit	Route
0.70	g	O

ADMET properties:

Property	Value	Reference
Vd (Volume of distribution)	6.69 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	13.55 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	23.82 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Sept. 19, 2019	EMA	GW Pharma (International) B.V.
June 25, 2018	FDA	GW RESEARCH LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Device related thrombosis	110.67	22.31	25	4345	1327	53343369
Drug resistance	70.93	22.31	34	4336	19928	53324768
Blood pressure diastolic decreased	67.03	22.31	31	4339	16772	53327924
Multiple-drug resistance	62.48	22.31	19	4351	3216	53341480
Large intestine polyp	59.28	22.31	23	4347	8074	53336622
Nail disorder	58.40	22.31	24	4346	9781	53334915
Body temperature decreased	43.43	22.31	23	4347	16604	53328092
Heart rate irregular	41.70	22.31	24	4346	20360	53324336
Tonic convulsion	40.73	22.31	11	4359	1220	53343476
Skin exfoliation	37.99	22.31	28	4342	36055	53308641
Blood pressure systolic increased	36.36	22.31	27	4343	35150	53309546
Urine leukocyte esterase positive	35.18	22.31	12	4358	2924	53341772
Hip fracture	34.50	22.31	24	4346	28233	53316463
Therapeutic product effective for unapproved indication	34.09	22.31	6	4364	86	53344610
Diarrhoea	33.04	22.31	119	4251	625427	52719269
Drug interaction	31.75	22.31	61	4309	219268	53125428
Drug level increased	31.34	22.31	20	4350	20401	53324295
Urine abnormality	29.17	22.31	13	4357	6447	53338249
Therapeutic product ineffective for unapproved indication	29.15	22.31	6	4364	204	53344492
Breast cancer metastatic	28.58	22.31	17	4353	15311	53329385
Infusion site scar	28.43	22.31	6	4364	231	53344465
Tri-iodothyronine free decreased	27.51	22.31	6	4364	270	53344426
Metastases to bone	27.37	22.31	18	4352	19310	53325386
Productive cough	27.00	22.31	28	4342	56701	53287995
Metastases to liver	25.63	22.31	18	4352	21478	53323218
Seizure	25.14	22.31	41	4329	129468	53215228
Cystic fibrosis	24.69	22.31	10	4360	3921	53340775
Creatinine urine decreased	23.65	22.31	5	4365	194	53344502

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Seizure	81.33	27.41	59	1865	103795	32407807
Drug interaction	65.57	27.41	72	1852	218113	32293489
Behaviour disorder	57.63	27.41	17	1907	3607	32507995
Social avoidant behaviour	38.02	27.41	12	1912	3187	32508415
Alcohol intolerance	33.02	27.41	7	1917	384	32511218
Prescription drug used without a prescription	29.16	27.41	8	1916	1307	32510295
Hyperacusis	28.29	27.41	7	1917	764	32510838
Off label use	28.00	27.41	58	1866	306262	32205340

Pharmacologic Action:

Source	Code	Description
ATC	N03AX24	NERVOUS SYSTEM ANTIEPILEPTICS ANTIEPILEPTICS Other antiepileptics
FDA CS	M0003267	Cannabinoids
MeSH PA	D000927	Anticonvulsants
MeSH PA	D002491	Central Nervous System Agents
FDA MoA	N0000182138	Cytochrome P450 1A2 Inhibitors
FDA MoA	N0000182139	Cytochrome P450 2B6 Inhibitors
FDA MoA	N0000182140	Cytochrome P450 2C19 Inhibitors
FDA MoA	N0000185504	Cytochrome P450 2C9 Inhibitors
FDA MoA	N0000187062	Cytochrome P450 2C8 Inhibitors
FDA MoA	N0000187064	Cytochrome P450 2B6 Inducers
FDA MoA	N0000191273	UGT2B7 Inhibitors
FDA MoA	N0000191278	UGT1A9 Inhibitors
CHEBI has role	CHEBI:76924	plant metabolites

Drug Use (View source of the data)

Disease	Relation	SNOMED_ID	DOID
Lennox-Gastaut syndrome	indication	230418006
Severe myoclonic epilepsy in infancy	indication	230437002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	9.34	acidic
pKa2	11.34	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11154516	June 17, 2034	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11154516	June 17, 2034	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10092525	June 17, 2035	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10111840	June 17, 2035	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10111840	June 17, 2035	USE FOR THE TREATMENT OF ATONIC SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10137095	June 17, 2035	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10137095	June 17, 2035	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10603288	June 17, 2035	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10603288	June 17, 2035	USE FOR REDUCING CONVULSIVE SEIZURE FREQUENCY IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10603288	June 17, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10603288	June 17, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10709671	June 17, 2035	USE FOR THE TREATMENT OF FOCAL SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10709674	June 17, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10709674	June 17, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10849860	June 17, 2035	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10849860	June 17, 2035	USE FOR THE TREATMENT OF DROP SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10966939	June 17, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10966939	June 17, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	9949937	June 17, 2035	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	9956183	June 17, 2035	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	9956183	June 17, 2035	USE IN COMBINATION WITH CLOBAZAM FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME WHO HAVE BEEN PREVIOUSLY TREATED WITH CLOBAZAM
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	9956184	June 17, 2035	USE IN COMBINATION WITH CLOBAZAM FOR TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	9956185	June 17, 2035	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	9956186	June 17, 2035	USE FOR THE TREATMENT OF CONVULSIVE SEIZURES IN PATIENTS WITH LENNOX GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10918608	Oct. 14, 2035	USE FOR REDUCING SEIZURE FREQUENCY IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10918608	Oct. 14, 2035	USE FOR THE TREATMENT OF GENERALIZED SEIZURES OR FOCAL SEIZURES WITH IMPAIRMENT IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	10918608	Oct. 14, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11065209	Oct. 14, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11096905	Oct. 14, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11096905	Oct. 14, 2035	USE FOR THE TREATMENT OF SEIZURES IN PATIENTS WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11207292	April 26, 2039	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH DRAVET SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11207292	April 26, 2039	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11207292	April 26, 2039	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	11160795	March 1, 2041	USE FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX IN PATIENTS TAKING EVEROLIMUS

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	July 31, 2023	NEW PATIENT POPULATION
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	Sept. 28, 2023	NEW CHEMICAL ENTITY
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	Sept. 28, 2025	INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	July 31, 2027	TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE
100MG/ML	EPIDIOLEX	GW RES LTD	N210365	Sept. 28, 2018	RX	SOLUTION	ORAL	July 31, 2027	TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Transient receptor potential cation channel subfamily V member 1	Ion channel	Q8NER1	TRPV1_HUMAN	INHIBITOR			UNKNOWN	SCIENTIFIC LITERATURE
G-protein coupled receptor 55	GPCR	Q9Y2T6	GPR55_HUMAN	ANTAGONIST	EC50	6.35	CHEMBL	SCIENTIFIC LITERATURE
N-arachidonyl glycine receptor	GPCR	Q14330	GPR18_HUMAN	AGONIST	EC50	4.29	IUPHAR
Cannabinoid receptor 1	GPCR	P21554	CNR1_HUMAN		Ki	5.62	CHEMBL
Transient receptor potential cation channel subfamily V member 2	Ion channel	Q9Y5S1	TRPV2_HUMAN	ACTIVATOR	EC50	4.50	IUPHAR
Cannabinoid receptor 2	GPCR	P34972	CNR2_HUMAN		Ki	5.54	CHEMBL
Cannabinoid receptor 1	GPCR		CNR1_RAT		Ki	5.90	CHEMBL
Cannabinoid receptor 2	GPCR		CNR2_MOUSE		Ki	6.64	CHEMBL
Transient receptor potential cation channel subfamily V member 2	Ion channel		TRPV2_RAT	ACTIVATOR	EC50	5.43	IUPHAR
Fatty-acid amide hydrolase 1	Enzyme		FAAH1_RAT		IC50	4.27	CHEMBL

External reference:

ID	Source
19GBJ60SN5	UNII
4036658	VANDF
C0006863	UMLSCUI
CHEBI:69478	CHEBI
P0T	PDB_CHEM_ID
CHEMBL190461	ChEMBL_ID
644019	PUBCHEM_CID
DB09061	DRUGBANK_ID
D002185	MESH_DESCRIPTOR_UI
D10915	KEGG_DRUG
4150	IUPHAR_LIGAND_ID
10423	INN_ID
2045371	RXNORM
010751	NDDF
771981005	SNOMEDCT_US
96223000	SNOMEDCT_US
20468	MMSL
291103	MMSL
d08919	MMSL

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Epidiolex	HUMAN PRESCRIPTION DRUG LABEL	1	70127-100	SOLUTION	100 mg	ORAL	NDA	31 sections
NanoCDB	HUMAN OTC DRUG LABEL	1	70658-122	SOLUTION/ DROPS	1.94 g	BUCCAL	Export only	8 sections
leafPro CBDmed Oil FS QP 3%	HUMAN OTC DRUG LABEL	1	73674-001	OIL	3 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil FS QP 5%	HUMAN OTC DRUG LABEL	1	73674-002	OIL	5 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil FS QP 20%	HUMAN OTC DRUG LABEL	1	73674-005	OIL	20 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil T-FS QD 3%	HUMAN OTC DRUG LABEL	1	73674-020	OIL	3 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil T-FS QD 5%	HUMAN OTC DRUG LABEL	1	73674-021	OIL	5 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Oil T-FS QD 20%	HUMAN OTC DRUG LABEL	1	73674-024	OIL	20 g	ORAL	unapproved drug other	15 sections
leafPro CBDmed Softgels FS QP 20	HUMAN OTC DRUG LABEL	1	73674-052	CAPSULE, LIQUID FILLED	20 mg	ORAL	unapproved drug other	15 sections
leafPro CBDmed Softgels T-FS QD 20	HUMAN OTC DRUG LABEL	1	73674-061	CAPSULE, LIQUID FILLED	20 mg	ORAL	unapproved drug other	15 sections
Kaydia Patch	HUMAN OTC DRUG LABEL	3	75140-002	PATCH	0.15 g	TOPICAL	unapproved drug other	8 sections